Gene-based antiangiogenic applications for corneal neovascularization

Area of Science:

• Ophthalmology
• Vascular Biology
• Gene Therapy

Background:

• Corneal avascularity is maintained by a balance of angiogenic and angiostatic factors.
• Pathological insults disrupt this balance, leading to corneal neovascularization (CNV), visual impairment, and graft failure.
• Current CNV treatments have limited efficacy and adverse effects.

Purpose of the Study:

• To review the pathogenesis of CNV and explore novel therapeutic strategies.
• To highlight the potential of gene-based and RNA-based therapies for CNV management.

Main Methods:

• Review of literature on corneal neovascularization.
• Analysis of gene transfer vector applications in animal models of CNV.
• Assessment of proangiogenic and antiangiogenic factors in experimental CNV.
• Evaluation of clinical trial data for antisense oligonucleotides in CNV.

Main Results:

• Gene transfer vectors have been utilized to target genes involved in CNV pathogenesis in preclinical models.
• Various proangiogenic and antiangiogenic factors have been investigated.
• Antisense oligonucleotides targeting CNV have advanced to human clinical trials without requiring vector delivery.

Conclusions:

• The cornea's unique anatomical and immune-privileged status makes it suitable for gene-based therapies.
• RNA-based strategies, such as antisense oligonucleotides, represent a significant advancement in managing CNV.
• These novel approaches herald a new era for ocular therapeutics in treating corneal neovascularization.